Online Program Home
My Program

Abstract Details

Activity Number: 231
Type: Topic Contributed
Date/Time: Monday, August 1, 2016 : 2:00 PM to 3:50 PM
Sponsor: Biometrics Section
Abstract #319624
Title: BOIN: A Simple, Ethical Bayesian Optimal Design for Phase I Oncology Trials
Author(s): Ying Yuan* and Suyu Liu
Companies: MD Anderson Cancer Center and MD Anderson Cancer Center
Keywords: phase I trial ; dose finding ; Bayesian design ; MTD ; drug combination

Despite more than two decades of publications that offer more innovative model-based designs, the classical 3+3 design remains the most dominant phase I trial design in practice. In this talk, we introduce a new trial design, the Bayesian optimal interval (BOIN) design. The BOIN design is easy to implement in a way similar to the 3+3 design, but is more flexible for choosing the target toxicity rate and cohort size, and yields substantially better performance that is comparable to that of more complex model-based designs. The BOIN design contains the 3+3 design and the accelerated titration design as special cases, thus linking it to established phase I approaches. A numerical study shows that the BOIN outperforms the 3+3 and mTPI designs with higher probability of correctly selecting the maximum tolerated dose and a lower risk of inadequately dosing patients or treating them at toxic doses. We also discuss the BOIN design for drug combination trials. Freely available, open-source software (R package "BOIN") is provided to facilitate the application of the BOIN designs.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

Copyright © American Statistical Association